Mount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
Retrieved on:
Monday, April 8, 2019
The second stimulant activates the dendritic cells, which then instruct T cells, the immune system's soldiers, to kill cancer cells and spare non-cancer cells.
Key Points:
- The second stimulant activates the dendritic cells, which then instruct T cells, the immune system's soldiers, to kill cancer cells and spare non-cancer cells.
- "The in situ vaccine approach has broad implications for multiple types of cancer," said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
- Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.
- For more information, visit http://www.mountsinai.org/ , or find Mount Sinai on Facebook, Twitter and YouTube.